Makers Laboratories Limited reported mixed financial results for FY26, with standalone operations showing a net loss of ₹1.72 crores despite consolidated net profit of ₹7.86 crores. Standalone performance declined with total income decreasing 5.4% to ₹5094.01 lakhs and net profit margin turning negative at -3.38%. However, consolidated revenue increased 7.3% to ₹14,230.44 lakhs, driven by strong performance from subsidiary Resonance Specialties Limited which reported revenue of ₹9199.93 lakhs and net profit of ₹1039.58 lakhs.
The company will hold its 41st Annual General Meeting on August 7, 2026, to adopt financial statements and seek shareholder approval for several matters. Key agenda items include reappointment of director Saahil Parikh and approval of related party transactions with Ipca Laboratories Limited up to ₹30 crores for FY27. The company also seeks ratification of cost auditor remuneration for Poddar & Co. at ₹1.5 lacs plus taxes.
Financial statements reveal significant segment divergence, with the pharmaceutical segment reporting PAT loss of ₹224.48 lakhs while the chemical manufacturing segment generated PAT of ₹1010.56 lakhs. The company maintained investments in mutual funds totaling ₹1157.40 lakhs and held term loans from Yes Bank at ₹206.22 lakhs with interest rates of 7.5-8.5%.
Regulatory impacts included implementation of new Labour Codes effective November 2025, which increased gratuity liability by ₹21.32 lakhs. The company maintains a 'CARE BBB+; Stable' credit rating for its ₹8.00 crores bank facilities. No dividend was recommended for FY26 due to standalone losses, and the company continues R&D focus on ophthalmic eye drops with expenditure of ₹21.27 lakhs (0.42% of turnover).